Akèy › Limfom Difize Gwo Selil B › Distrik Columbia › Washington
Etid klinik pou Limfom Difize Gwo Selil B nan Washington, DC
12 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
- MedStar Georgetown University Hospital, Washington D.C.
- The Center for Cancer and Blood Disorders, Bethesda · 7 mi lwen
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- American Oncology Partners of Maryland Pa, Bethesda · 7 mi lwen
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Ap rekriteFaz 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
- American Oncology Partners, P.A. ( Site 0185), Bethesda · 7 mi lwen
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- Georgetown University Medical Center ( Site 0117), Washington D.C.
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Medstar Georgetown University Hospital, Washington D.C.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- MedStar Georgetown University Hospital, Washington D.C.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- National Institute of Health, Bethesda · 7 mi lwen
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Los Angeles, CA17 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Portland, OR15 etid
- Nashville, TN15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Dallas, TX13 etid
Lòt etid nan Washington
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil55 etid
- Kansè nan tete46 etid
- Kansè Metastatik43 etid
- Kansè poumon41 etid
- Kansè pwostat38 etid
- Obèsite33 etid
- Kansè kolorektal29 etid
- Maladi kadyovaskilè29 etid
- Kansè vejik26 etid
- Leksemi mieloïd egi24 etid
- Limfom23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.